Gastrointestinal manifestations of systemic sclerosis

被引:88
作者
Domsic, Robyn [2 ]
Fasanella, Kenneth [1 ]
Bielefeldt, Klaus [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Med, Div Rheumatol, Pittsburgh, PA 15213 USA
关键词
dysmotility; gastroesophageal reflux; pseudo-obstruction; systemic sclerosis;
D O I
10.1007/s10620-007-0018-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Systemic sclerosis is a chronic disorder of connective tissue that affects the gastrointestinal tract in more than 80% of patients. Changes in neuromuscular function with progressive fibrosis of smooth muscle within the muscularis propria impair normal motor function, which may secondarily alter transit and nutrient absorption. Esophageal manifestations with gastroesophageal reflux and dysphagia are the most common visceral manifestation of the disease, often requiring more intense acid-suppressive medication. Gastric involvement may lead to gastroparesis, which can be found in up to 50% of patients. Severe small bowel disease can present as chronic intestinal pseudo-obstruction with distended loops of small intestine, bacterial overgrowth, impaired absorption and progressive development of nutritional deficiencies. While not studied as extensively, systemic sclerosis often also affects colorectal function resulting in constipation, diarrhea or fecal incontinence. Nutritional support and prokinetics have been used with some success to manage gastric and small or large bowel involvement in patients with systemic sclerosis. Despite advances in management, significant gastrointestinal manifestations of systemic sclerosis still carry a poor prognosis with a five-year mortality exceeding 50%.
引用
收藏
页码:1163 / 1174
页数:12
相关论文
共 85 条
[1]
Oesophageal manometry in early and definite systemic sclerosis [J].
Airò, P ;
Della Casa, D ;
Danieli, E ;
Missale, G ;
Cattaneo, R ;
Cestari, R .
CLINICAL RHEUMATOLOGY, 2005, 24 (04) :370-376
[2]
Is scleroderma an autoantibody mediated disease? [J].
Arnett, Frank C. .
CURRENT OPINION IN RHEUMATOLOGY, 2006, 18 (06) :579-581
[3]
Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea:: A crossover, randomized trial [J].
Attar, A ;
Flourié, B ;
Rambaud, JC ;
Franchisseur, C ;
Ruszniewski, P ;
Bouhnik, Y .
GASTROENTEROLOGY, 1999, 117 (04) :794-797
[4]
Oesophageal acid clearance in patients with systemic sclerosis: Effect of body position [J].
Basilisco, G ;
Carola, F ;
Vanoli, M ;
Bianchi, P ;
Barbera, R .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (03) :205-209
[5]
Esophageal dysfunction in scleroderma - Relationship with disease subsets [J].
Bassotti, G ;
Battaglia, E ;
Debernardi, V ;
Germani, U ;
Quiriconi, F ;
Dughera, L ;
Buonafede, G ;
Puiatti, P ;
Morelli, A ;
Spinozzi, F ;
Mioli, PR ;
Emanuelli, G .
ARTHRITIS AND RHEUMATISM, 1997, 40 (12) :2252-2259
[6]
Boeckxstaens GE, 2002, AM J GASTROENTEROL, V97, P194
[7]
Faecal incontinence [J].
Chatoor, D. R. ;
Taylor, S. J. ;
Cohen, C. R. G. ;
Emmanuel, A. V. .
BRITISH JOURNAL OF SURGERY, 2007, 94 (02) :134-144
[8]
Mechanisms and consequences of fibrosis in systemic sclerosis [J].
Denton, CP ;
Black, CM ;
Abraham, DJ .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (03) :134-144
[9]
Scleroderma and related disorders: therapeutic aspects [J].
Denton, CP ;
Black, CM .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2000, 14 (01) :17-35
[10]
DESCHRYVERKECSKEMETI K, 1989, ARCH PATHOL LAB MED, V113, P394